

### **Parallelization of MCMC based Phylogenetic analysis to greatly reduce run time**

**BioNet November Seminar** 

Presented by: David Yang MSc. Student University of Calgary

**November 15th 2023**

Introduction

# Table of Content



Methods

Results



hh.

Conclusion



## **Introduction**

### **Phylogenetic analysis**



Phylogenetics is the study of **evolutionary history** and relationships through the analysis of heritable traits such as **genomic sequences**



### **Relevance to COVID-19 Pandemic**



Viral agent of COVID-19: **SARS-CoV-2** 

Outcomes from phylogenetic analyses (genomic epidemiology):

- Probable zoonotic origin was found
- Elucidation of multiple episodes of the Founder effect during the early pandemic
- Identification of Infection sources, "superspreaders" and asymptomatic individuals



### **Bayesian Phylogenetics**



Advantageous over conventional methods especially for **viral outbreaks** Incorporates existing knowledge through various **prior models**:



**Assumption:** sampled individual does not remain infectious

 $λ$  – transmission rate δ – rate of becoming non-infectious

#### **Birth-death skyline model Generalised time reversible model**



### **Limitations with Phylogenetic Analysis**



Inference through phylogenetic analyses is a complex and exhaustive process:



The goal to obtain the **maximum clade credibility** (MCC) tree - most reasonable evolutionary relation given the estimated Bayesian parameters Often accompanies long run-times and intensive computational demand

### **Current methods**



Many studies have proposed optimization methods:

- **RAxML** provides features for parallelizing maximum likelihood calculations to speed up computations
- **matOptimize**, which was inspired by the overwhelmingly number of SARS-CoV-2 sequences available, also optimizes maximum parsimony based phylogenetic analyses through parallelization and memory-efficient data structures

Lack of significant breakthroughs in terms reducing run-times for Bayesian phylogenetic analyses



### **In this paper, we propose a parallelization method for Bayesian phylogenetic analysis using BEAST2**



# **Methodology**

#### **Datasets**



Simulation data: Two HIV1 simulated sequence datasets each with 10 subsamples of 1000 sequences were generated with the simulation software FAVITES using established parameters for HIV from literature:

- i. 1<sup>st</sup> dataset perfect sequence sampling
- ii. 2<sup>nd</sup> dataset 10% sequence sampling rate

SARS-CoV-2 data: Six total subsamples of 1000 sequences of SARS-CoV-2 were obtained from GISAID database using random (Augur) and weighted (Nybbler) sampling from February  $1<sup>st</sup>$ , 2020 to October 31 $<sup>st</sup>$ , 2020.</sup>

### **Software used**



- **MAFFT**: create multiple sequence alignments for nucleotide sequences
- **Beauti**: Configuration for BEAST2 analysis
- **BEAST2**: Bayesian analysis of molecular sequences
- **Logcombiner:** Combining the output from multiple BEAST2 runs
- **Treeannotator**: Finding maximum clade credibility tree
- **TreeCMP**: Calculating similarity between phylogenetic trees

#### **Parallel Computation**

**Figure 1**: Overview of the Bayesian phylogenetic analyses performed in the study. Differences in methodology between MCMC ran in parallel and sequentially are shown along with the corresponding run -time for each step in the procedure.



**Sequential Computation** 



### **Analysis of results (difference between parallel and sequential)**



Two main components:

- 1. Comparison of parameter estimates (i.e., substitution rates & gamma rate parameter) from parallel computations with sequential computations and/or ground-truth
- 2. Comparison of phylogenetic trees (i.e., distance metrics) from parallel computations with sequential computations and/or ground-truth

Statistical tests such as U-test and T-test were performed to check significance



## **Results**



# **Simulation dataset #1 – perfect sampling**



**Figure 2:** Boxplots from ten parameter estimates from MCMC phylogenetic analyses ran in parallel and sequentially on simulated HIV data with perfect sampling rate. Significant p-values from the U-test (as a line) and t-test (directly above) are labelled. Figures with different vertical axis scaling were used due to differences in the ranges of values.

### **GTR estimates**

**Figure 3** : Violin plots from parameter estimates from twenty -nine independent MCMC chains (100 -million iterations) from the phylogenetic analysis performed on the first replicate of sequences in the HIV dataset perfect sampling rate . The parameter estimates for all 29 MCMC chains combined ("combined") and parameter estimates from the MCMC run sequentially ("sequential") on the same dataset are also shown . Horizontal dashed lines represent the true value (standard) for each parameter .





**Figure 4 :** Boxplots from ten distance metrics calculated by comparing MCC phylogenetic trees obtained from MCMC with "true" trees defined in the simulated HIV data with perfect sampling rate. Significant p-values from the U-test comparing the distances from the sequential and parallel samples are labelled.



# **Simulation dataset #2 – 10% sampling**



**Figure 5:** Boxplots from parameter estimates from MCMC phylogenetic analyses ran in parallel and sequentially on simulated HIV data with 10% sampling rate. Significant p-values from the U-test (as a line) and t-test (directly above) are labelled. Figures with different vertical axis scaling were used due to differences in the ranges of values

### **GTR estimates**

**Figure 6** : Violin plots of parameter estimates from twenty -nine independent MCMC chains (100 -million iterations) from the phylogenetic analysis performed the first replicate of sequences in the HIV dataset 10 sampling rate. . The parameter estimates for all 29 MCMC chains combined ("combined") and parameter estimate from the MCMC ran sequentially ("sequential") on the same data are also shown . Horizontal dashed lines represent the true value (standard) for each parameter .





**Figure 7:** Boxplots from ten distance metrics calculated by comparing MCC phylogenetic trees obtained from MCMC with "true" trees defined in the simulated HIV data with 10% sampling rate. Significant p-values from the U-test comparing the distances from the sequential and parallel samples are labelled.



## **Real world dataset – SARS-CoV-2**



**Figure 8**: Boxplots from six parameter estimates from MCMC phylogenetic analyses ran in parallel and sequentially on SARS-CoV-2 data. Significant p-values from the U-test (as a line) and t-test (directly above) are labelled.



**Figure 9:** Boxplots from distance metrics calculated by comparing MCC phylogenetic trees obtained from sequential and parallel MCMC runs on simulated HIV data with perfect sampling, simulated HIV data with 10% sampling rate, and SARS-CoV-2 data. Significant p-values from the U-test comparing the distances between the metrics from each dataset are labelled.



## **Conclusion**

### **Final remarks**



Overall experimental run-times were **reduced by almost 84 days** owing to the parallelization

#### Parameter estimates:

- The sequential MCMC runs provided **no significant advantage** predicting phylogenetic parameters over the parallel MCMC runs in our analyses involving simulated data
- Even in the parameter estimates from SARS-CoV-2 data, **no significant differences** in parameter estimates were observed

#### Phylogenetic tree predictions:

- Distance metrics calculated in the simulation study also suggested that MCC phylogenetic trees obtained from parallel and sequential MCMC were **mostly similar** except for branch lengths
- In general, our parallelization methodology was less consistent for the real-world SARS-CoV-2 data
- Most of the differences lay in the scaling of the phylogenetic trees and not in the topology of the phylogenetic trees for the simulation dataset whereas in the SARS-CoV-2 dataset, differences were found in the topology as well





Supervisor: **Dr. Paul Gordon**

Support from **Dr. Qingrun Zhang** & **Dr. Quan Long** and other lab members

Funding: Alberta Innovates



### **Thank you for attending!**

**Feel free to ask any questions!**

David Yang For any inquiries I may be reached at [david.yang1@ucalgary.ca](mailto:david.yang1@ucalgary.ca)



#### **Methodology**

Random sampling

• Randomly select *N* sequences from all sequence data available

#### Weighted sampling

- Select *N* sequences from each country in each month based on SARS-CoV-2 prevalence
- Prevalence estimated with IHME mean estimates

### **Site models**







### **Differences in Clock Rate**

